title: Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancers: a multiple-threshold method for [(18)F]fluoro-2-deoxyglucose activity.
abstract: OBJECTIVE
  Clinical applicability of a multiple-threshold method for [(18)F]fluoro-2-deoxyglucose (FDG) activity in radiation treatment planning was evaluated.
  
  
  METHODS
  A total of 32 patients who underwent positron emission and computed tomography (PET/CT) simulation were included; 18 patients had lung cancer, and 14 patients had pharyngeal cancer. For tumors of <or=2 cm, 2 to 5 cm, and >5 cm, thresholds were defined as 2.5 standardized uptake value (SUV), 35%, and 20% of the maximum FDG activity, respectively. The cervical and mediastinal lymph nodes with the shortest axial diameter of >or=10 mm were considered to be metastatic on CT (LNCT). The retropharyngeal lymph nodes with the shortest axial diameter of >or=5 mm on CT and MRI were also defined as metastatic. Lymph nodes showing maximum FDG activity greater than the adopted thresholds for radiation therapy planning were designated LNPET-RTP, and lymph nodes with a maximum FDG activity of >or=2.5 SUV were regarded as malignant and were designated LNPET-2.5 SUV.
  
  
  RESULTS
  The sizes of gross tumor volumes on PET (GTVPET) with the adopted thresholds in the axial plane were visually well fitted to those of GTV on CT (GTVCT). However, the volumes of GTVPET were larger than those of GTVCT, with significant differences (p < 0.0001) for lung cancer, due to respiratory motion. For lung cancer, the numbers of LNCT, LNPET-RTP, and LNPET-2.5 SUV were 29, 28, and 34, respectively. For pharyngeal cancer, the numbers of LNCT, LNPET-RTP, and LNPET-2.5 SUV were 14, 9, and 15, respectively.
  
  
  CONCLUSIONS
  Our multiple thresholds were applicable for delineating the primary target on PET/CT simulation. However, these thresholds were inaccurate for depicting malignant lymph nodes.
authors.affiliation: Department of Radiation Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Okubo
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Nishimura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Nakamatsu
authors.forename: Masahiko
authors.initials: M
authors.lastname: Okumura
authors.forename: Toru
authors.initials: T
authors.lastname: Shibata
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kanamori
authors.forename: Kouhei
authors.initials: K
authors.lastname: Hanaoka
authors.forename: Makoto
authors.initials: M
authors.lastname: Hosono
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy; D008198:Lymph Nodes / Q000000981:diagnostic imaging*; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D010610:Pharyngeal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D011880:Radiotherapy Planning, Computer-Assisted; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000379:methods; D047368:Tumor Burden; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18